Translational Sciences Inc.
- Biotech or pharma, therapeutic R&D
Translational Sciences develops highly specific, monoclonal antibodies to improve outcomes for patients with ischemic and hemorrhagic stroke, bleeding (traumatic or surgical), heart failure, etc. TS seeks a partnership to accelerate development of TS91, a first-in-class monoclonal antibody for the treatment of hemorrhagic stroke (orphan disease) and ischemic stroke. Of note, TS23, our first monoclonal antibody, is now in multicenter Phase II clinical trials for treatment of ischemic stroke and pulmonary embolism.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}